Biogen Inc. $BIIB Position Lifted by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. raised its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 3,284.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,780 shares of the biotechnology company’s stock after acquiring an additional 48,309 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Biogen were worth $11,244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. BlackRock Inc. purchased a new position in Biogen during the second quarter valued at $3,453,878,000. Orbimed Advisors LLC bought a new stake in Biogen during the first quarter valued at about $11,293,000. Tidal Investments LLC grew its holdings in Biogen by 9.0% during the second quarter. Tidal Investments LLC now owns 63,842 shares of the biotechnology company’s stock valued at $13,794,000 after purchasing an additional 5,256 shares during the period. Nippon Life Global Investors Americas Inc. purchased a new stake in Biogen in the second quarter worth about $29,648,000. Finally, Saudi Central Bank increased its position in Biogen by 89.7% in the second quarter. Saudi Central Bank now owns 10,273 shares of the biotechnology company’s stock worth $2,220,000 after buying an additional 4,858 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

NASDAQ:BIIB opened at $253.84 on Friday. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $37.50 billion, a P/E ratio of 44.93, a P/E/G ratio of 2.68 and a beta of 0.09. Biogen Inc. has a 12 month low of $138.00 and a 12 month high of $254.41. The business’s 50-day moving average is $222.78 and its 200 day moving average is $205.73.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. The company had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The firm’s revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the company earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities research analysts forecast that Biogen Inc. will post 12.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BIIB shares. Morgan Stanley raised their price objective on Biogen from $222.00 to $231.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Royal Bank Of Canada cut their price objective on Biogen from $260.00 to $256.00 and set an “outperform” rating for the company in a research note on Thursday, October 8th. Wells Fargo & Company increased their target price on shares of Biogen from $250.00 to $310.00 and gave the stock an “overweight” rating in a report on Tuesday. Seaport Research Partners raised shares of Biogen to an “outperform” rating in a report on Monday, October 12th. Finally, HC Wainwright raised their target price on shares of Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.89.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Wells Fargo raised its price target on Biogen, adding to a series of upward analyst revisions and reinforcing optimism about the company’s outlook. Biogen Stock Gets Price Target Boost from Wells Fargo
• Positive Sentiment: Bank of America increased its Biogen price target to $244 from $219. Although the firm maintained a Neutral rating, the revision reflects improved expectations as analysts update their models ahead of earnings. Biogen on BofA Price Target Hike
• Positive Sentiment: Several previews suggest Biogen could exceed third-quarter earnings estimates, supported by favorable analyst expectations and the potential for continued progress across its late-stage drug pipeline. Biogen Expected to Beat Earnings Estimates
• Neutral Sentiment: Wedbush kept a Hold rating on Biogen, indicating that valuation and near-term catalysts may already be reflected in the share price. Wedbush Remains a Hold on Biogen
• Negative Sentiment: Bank of America’s $244 target remains below the stock’s recent trading level, implying limited upside or potential downside despite the target increase. Analysts also characterize the upcoming quarter as relatively quiet, and earnings previews warn that disappointment remains possible.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.